In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka Weighs Family Influence In Wake Of Successful IPO

This article was originally published in PharmAsia News

Executive Summary

Otsuka Holdings made a successful debut on the Tokyo Stock Exchange, but that also means it will be watched to see if it adheres to the policies of its founding family

You may also be interested in...



Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC

EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.

AZ and GSK Dip Into Diagnostics To Support COVID-19 UK Tests

The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.

Angelini Sets Up In Germany As It Unveils ThermaCare Plans

Angelini is looking to take its recently-acquired ThermaCare brand to the next level by establishing a direct base in Germany to market the product and through a new distribution deal with Norway's Navamedic.

UsernamePublicRestriction

Register

SC073825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel